Table 1. HSIL and CANCER prevalence by HPV type.

HPV TYPE	HSIL		CANCER		CANCER∶HSIL
	N° of patients	Prevalence %	N° of patients	Prevalence %	Prevalence
	(N° of Studies)	(95% CI)	(N° of Studies)	(95% CI)	ratio
Global	2446 (52)		5540 (62)
Any	1749 (36)	82.5 (77.3–87.1)	3435 (43)	89.0 (84.3–92.9)	1.08
Type 6	1415 (29)	4.2 (2.2–6.7)	2274 (32)	1.7 (0.9–2.8)	0.4
Type 11	1414 (29)	2.4 (1.3–3.8)	2274 (32)	1.3 (0.5–2.5)	0.54
Type 16	2327 (49)	46.5 (41.3–51.7)	5463 (60)	53.2 (49.1–57.2)	1.14
Type 18	2194 (45)	8.9 (6.3–11.8)	4962 (56)	13.2 (11.0–15.6)	1.48
Type 31	1785 (36)	8.0 (6.0–10.4)	3903 (45)	7.5 (5.5–9.8)	0.94
Type 33	1722 (35)	6.5 (4.7–8.5)	3821 (42)	4.3 (3.2–5.5)	0.66
Type 35	1228 (24)	3.0 (1.9–4.4)	2332 (31)	2.0 (1.3–2.7)	0.67
Type 39	885 (20)	2.4 (1.5–3.5)	1977 (27)	1.8 (1.3–2.4)	0.75
Type 45	1077 (24)	3.9 (2.8–5.2)	3389 (37)	4.6 (3.5–5.7)	1.18
Type 51	1013 (21)	3.7 (2.1–5.7)	2131 (30)	2.1 (1.1–3.3)	0.57
Type 52	1152 (25)	4.9 (2.9–7.4)	2544 (34)	3.2 (2.1–4.4)	0.65
Type 56	892 (19)	2.4 (1.5–3.4)	2155 (28)	1.2 (0.8–1.7)	0.5
Type 58	1197 (26)	8.7 (6.0–11.9)	2564 (34)	3.0 (2.1–4.1)	0.34
Type 59	954 (21)	1.9 (1.2–2.9)	2199 (30)	1.6 (1.1–2.2)	0.84
Type 66	926 (20)	1.8 (1.1–2.8)	2095 (28)	1.1 (0.7–1.6)	0.61
Type 68	619 (14)	1.3 (0.6–2.3)	1864 (23)	0.5 (0.3–0.9)	0.38
Other*	1479 (32)	11.6 (7.6–16.2)	3177 (34)	7.5 (5.0–10.4)	0.65
Multiple	1431 (29)	16.8 (12.9–21.2)	2090 (27)	12.6 (8.7–17.2)	0.75